Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects

NCT00116662 is registered in ClinicalTrials.gov with Graceway Pharmaceuticals, LLC as lead sponsor.

NCT NCT00116662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects
Lead sponsor
Graceway Pharmaceuticals, LLC
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
Not reported
Enrollment
84
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

warts